This firm is publicly traded on the OTC Bulletin Board. Information on individual stock prices can be accessed from the symbol, but firms in this category are not part of SBIR Index. Oncor was in the development and marketing of reagents, molecular biology products and diagnostic products for the detection and management of certain cancers. In February 1999 Oncor Inc. sold to Canadian company its 80% interest in Appligene Oncore, a French company, . After sale of Appligene, the Company's only remaining assets consisted of certain Oncor and Codon intellectual property and licenses. The future uses, if any, of these remaining assets is being explored by the company. In February 1999, Oncor, Inc. and its wholly-owned subsidiary, Codon Pharmaceuticals, Inc., filed voluntary petitions for relief under Chapter 11 of the United States Code with the United States Bankruptcy Court for the District of Delaware, Wilmington, DE.
